Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul F. Lizzul Insider Profile
4 Followers
Paul F. Lizzul, CMO at Sienna Biopharmaceuticals, holds 15.40K shares in AnaptysBio (Ticker: ANAB), holds 207.04K shares in Sienna Biopharmaceuticals (Ticker: SNNAQ).
Paul F. Lizzul has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Paul F. Lizzul holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Paul F. Lizzul
Paul F. Lizzul's Trading History
Sienna Biopharmaceuticals
Aug 08, 2019
CMO
Uninformative Buy
―
$2.07K
AnaptysBio
Sep 17, 2024
CMO
Uninformative Buy
152.45K
$563.10K
List of latest transactions for each holding click on a transaction to see Paul F. Lizzul's performance on stock
You May Also Like
Paul F. Lizzul insider profile FAQ
What is the percentage of profitable transactions made by Paul F. Lizzul?
The percentage of profitable transactions made by Paul F. Lizzul is ―.
What is the average return per transaction made by Paul F. Lizzul?
The average return per transaction made by Paul F. Lizzul is ―.
What stocks does Paul F. Lizzul hold?
Paul F. Lizzul holds: SNNAQ, ANAB stocks.
What was Paul F. Lizzul’s latest transaction?
Paul F. Lizzul latest transaction was an Uninformative Buy of $152.45K.
What was Paul F. Lizzul's most profitable transaction?
Paul F. Lizzul’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Paul F. Lizzul's role in Sienna Biopharmaceuticals?
Paul F. Lizzul's role in Sienna Biopharmaceuticals is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.